Riskpilot← Back to searchSign inGet full accessDirect Derma Supplies ApS
APSActiveCVR 37575003Axeltorv 2F, 5.Wholesale of pharmaceutical and medical goods · NACE 4646Est. 201615 employeeshttps://www.directdermasupplies.com/
Revenue 2025
DKK 17,6M
+7% vs 2024
EBITDA margin
64.5%
+7% vs 2024
Equity ratio
45.2%
Financial strength
Net profit 2025
DKK 8,7M
+7% vs 2024
| Revenue | DKK 17,6M | +7% |
| EBITDA | DKK 11,4M | +7% |
| Net profit | DKK 8,7M | +7% |
| Total assets | DKK 21,5M | +47% |
| Equity | DKK 9,7M | +12% |
| Employees | 15 | — |
Legal name
Direct Derma Supplies ApS
CVR number
37575003
Legal form
Anpartsselskab
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
31. marts 2016
Share capital
DKK 50.000
Employees
15 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2025-06-30
Financial year
January – December
Signatory rights
Selskabet tegnes af bestyrelsesformanden i forening med den administrerende direktør, af bestyrelsesformanden i forening med ét bestyrelsesmedlem, af tre bestyrelsesmedlemmer i forening eller af den samlede bestyrelse.
Company purpose
Selskabets formål er - direkte eller via besiddelse af kapitalandele i andre selskaber - at drive handel med medicinsk udstyr og andre kosmetiske produkter og anden virksomhed, der efter bestyrelsens skøn er forbundet dermed.
Address
Axeltorv 2F, 5.
Phone
+4573708111
Email
contact@directdermasupplies.com
Website
https://www.directdermasupplies.com/
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.479 | 6.623 | 11.510 | 13.669 | 17.687 | 19.466 | 16.278 | 16.543 | 17.639 |
| Staff expenses | -1.089 | -2.306 | -2.555 | -2.913 | -3.509 | -5.517 | -5.606 | -5.934 | -6.262 |
| EBITDA | 390 | 4.317 | 8.955 | 10.756 | 14.178 | 13.949 | 7.697 | 10.593 | 11.377 |
| Depreciation & amort. | 32 | -0 | -67 | -102 | -107 | -107 | -107 | -40 | -93 |
| EBIT | 358 | 4.317 | 8.888 | 10.654 | 14.071 | 13.842 | 7.590 | 10.553 | 11.284 |
| Net financials | -3 | -77 | -45 | -84 | -114 | -297 | -115 | -32 | -81 |
| Profit before tax | 355 | 4.240 | 8.843 | 10.570 | 13.957 | 13.544 | 7.475 | 10.521 | 11.203 |
| Tax | 89 | 940 | 1.954 | 2.332 | 3.075 | 2.984 | 2.092 | 2.337 | 2.475 |
| Net profit | 266 | 3.300 | 6.889 | 8.238 | 10.882 | 10.561 | 5.383 | 8.184 | 8.728 |
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Total assets | 1.620 | 5.352 | 11.856 | 12.845 | 16.476 | 16.599 | 13.148 | 14.602 | 21.499 |
| Equity | 316 | 3.386 | 7.639 | 8.988 | 12.132 | 12.561 | 7.883 | 8.684 | 9.728 |
| Long-term debt | 0 | 0 | 1.427 | 2.333 | 3.217 | 2.985 | 3.450 | 2.333 | 2.234 |
| Short-term debt | 1.304 | 1.965 | 2.742 | 1.477 | 1.077 | 1.005 | 1.737 | 1.494 | 7.206 |
| Total debt | 1.304 | 1.965 | 4.170 | 3.810 | 4.294 | 3.990 | 5.187 | 3.828 | 9.440 |
EBITDA margin
64.5%
This company
15.8%
Market median
+308% vs market
20172025
Equity ratio
45.2%
This company
38.2%
Market median
+18% vs market
20172025
Return on equity
89.7%
This company
18.4%
Market median
+388% vs market
20172025
Net profit margin
49.5%
This company
8.1%
Market median
+511% vs market
20172025
Asset turnover
0.82×
This company
1.12×
Market median
+27% vs market
20172025
Debt / equity
1.21×
This company
0.62×
Market median
-95% vs market
20172025
- Annual report 2025Filed via CVR / Virk · Period 2024-07-01 – 2025-06-30
- Annual report 2024Filed via CVR / Virk · Period 2023-07-01 – 2024-06-30
- Annual report 2023Filed via CVR / Virk · Period 2022-07-01 – 2023-06-30
- Annual report 2022Filed via CVR / Virk · Period 2021-07-01 – 2022-06-30
- Annual report 2021Filed via CVR / Virk · Period 2020-07-01 – 2021-06-30
- Annual report 2020Filed via CVR / Virk · Period 2019-07-01 – 2020-06-30
- Annual report 2019Filed via CVR / Virk · Period 2018-07-01 – 2019-06-30
- Annual report 2018Filed via CVR / Virk · Period 2017-07-01 – 2018-06-30
- Annual report 2017Filed via CVR / Virk · Period 2016-03-31 – 2017-06-30
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
PW Chief Executive Officer | Chief Executive Officer | 2022 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2018 | — | — | |
| Board of Directors | 2018 | — | — | |
| Board of Directors | 2018 | — | — | |
| Chairman | 2018 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
NMS Group A/S | Company | 100.0% | 100.0% | 2020 |
Ginnerup Capital ApS | Company | 10.0% | 10.0% | 2018 |
CASPER TINGKÆR HOLDING ApS | Company | 33.3% | 33.3% | 2018 |
Ginnerup Company ApS | Company | 33.3% | 33.3% | 2018 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Ginnerup Company ApS
Direct Derma Supplies ApS Board members of Direct Derma Supplies ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Pernille Wandrup Rex | Chief Executive Officer | 0 companies |
| Philip Schiermacher Stavnstrup | Board of Directors | 0 companies |
| Christa Bormann | Board of Directors | 0 companies |
| Casper Henrique Tingkær | Board of Directors | 0 companies |
| Monica Reib | Board of Directors | 0 companies |
| Kim Erik Ginnerup | Chairman | 0 companies |